Exclusive: Shinobi raises $51M to take on cell therapy challenges with ex-Wugen CEO at helm, Carl June in support

Shinobi Therapeutics is trying to live up to its moniker, named after the Japanese word for ninja.

The biotech — a merger of two startups from Kyoto, Japan and the Bay Area — aims to create off-the-shelf cell therapies that can be re-dosed and delivered without requiring immunosuppressive drugs, which…
Click here to view original post